Tag: obesity
Daily Blogwatch: Are All Hedge Funds Scams?
by James Altucher on Sep.07, 2010, under Towing
Among Tuesday's top stories for investors: How do dividend-paying stocks stack up against non-dividend-paying stocks? Is Facebook making it easier for stalkers? Are all hedge funds scams?
Continue reading Daily Blogwatch: Are All Hedge Funds Scams?
Daily Blogwatch: Are All Hedge Funds Scams? originally appeared on DailyFinance on Tue, 07 Sep 2010 08:30:00.
Filed Under: Columns, InvestingOrexigen Shares Soar on Partnership Deal With Takeda
by Melly Alazraki on Sep.02, 2010, under Towing
Orexigen jumped over 25% in premarket trading after announcing an exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda Pharmaceutical to develop and commercialize Contrave, Orexigen's promising obesity drug.
Continue reading Orexigen Shares Soar on Partnership Deal With Takeda
Orexigen Shares Soar on Partnership Deal With Takeda originally appeared on DailyFinance on Thu, 02 Sep 2010 09:00:00.
Filed Under: Company News, Investing, Health Care, Stocks in the News‘Fructose-Slurping’ Cancer Could Sour the Soda Business
by Sarah Gilbert on Aug.13, 2010, under Towing
Soda and processed-food makers insist that all sugars are the same. Yet with studies linking fructose to obesity, diabetes and, most recently, pancreatic cancer, big brands are quietly backing away from using corn-based high-fructose sweetener. Could it eventually become another tobacco-like liability?
Continue reading 'Fructose-Slurping' Cancer Could Sour the Soda Business
'Fructose-Slurping' Cancer Could Sour the Soda Business originally appeared on DailyFinance on Fri, 13 Aug 2010 13:45:00.
Filed Under: Columns, Health Care, Coca-Cola Company, Pepsico, StarbucksDaily Blogwatch: Which S&P 500 Stock Do Analysts Love Best?
by James Altucher on Aug.06, 2010, under Towing
Some of the best reads for investors from around the Web, including the stock with the best analyst rating on the Standard & Poor's 500, Bill Gates's 10 life rules and what the next Warren Buffett is buying.
Continue reading Daily Blogwatch: Which S&P 500 Stock Do Analysts Love Best?
Daily Blogwatch: Which S&P 500 Stock Do Analysts Love Best? originally appeared on DailyFinance on Fri, 06 Aug 2010 08:30:00.
Filed Under: Columns, Investing, Health Care, Media, Goldman Sachs , Stock Picks, New York Times CoVivus Hammered After FDA Panel’s ‘No’ Vote; Orexigen Down, Arena Up
by Melly Alazraki on Jul.16, 2010, under Towing
Pharmaceutical company Vivus is getting hammered in Friday tading, sinking more than 50% in the wake of Thursday's vote by an FDA advisory panel against approving its weight-loss drug, Qnexa, based on safety concerns.
Continue reading Vivus Hammered After FDA Panel's 'No' Vote; Orexigen Down, Arena Up
Vivus Hammered After FDA Panel's 'No' Vote; Orexigen Down, Arena Up originally appeared on DailyFinance on Fri, 16 Jul 2010 08:47:00.
Filed Under: Investing, Health Care, Biz Brief